wellwoman
Latisse: First Eyelash Thickener, FDA-Approved
Filed in archive Beauty by Gloria Gamat on December 30, 2008
A product of Allergan - Latisse - the first eyelash grower/thickener drug — is now approved by the FDA.

Latisse, which will be available by prescription starting in the first quarter of 2009, contains the active ingredient of the glaucoma drug Lumigan, which is also made by ALLERGAN.

Eyelash growth is a known side effect of Lumigan. But Lumigan and Latisse are used differently. Lumigan is an eyedrop, and Latisse gets dabbed along the lash line on the upper eyelids to promote longer, thicker, darker lashes.


Deborah Kotz wrote at the U.S. News and World Report Blog:

This drug is meant for those with a real (and often genetic) health problem called hypotrichosis, in which no hair grows on the eyelid. It may also be useful for those who've suffered permanent eyelash loss because of chemotherapy or other medical treatments.


Yes there is a condition (hyprotrichosis) wherein no hair grows on the eyelids. I just hope that Latisse is not mistaken as a solution to a beauty regimen when women just wanna have longer eyelashes for the heck of it.



Permalink: Latisse: First Eyelash Thickener, FDA-Approved
Tags: Latisse  Allergan  eyelash  thickener  eyelash  grower  eyelashes  latisse  eyelash+thickener 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/140438
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Latisse: First Eyelash Thickener, FDA-Approved:

  • Currently 4.25/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 4.25 out of 4 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!